NCT01704703已完成2 期
Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques.
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Objective response rate (TRO)
研究概览
简要总结
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Competent to understand, sign and date an IEC-approved informed consent form.
- •Men or women 18 years of age or older at the time the written informed consent is obtained.
- •Histologically confirmed metastatic adenocarcinoma of the colon or rectum Wild-Type RAS (No mutation) with at least 1 measurable metastatic lesion following RECIST criteria v 1.1 and initially irresectable (non suitable for radical surgery at the inclusion time).
- •Obtention of DNA from tumor tissue blocks sent to central lab (ICO) that is amenable for highly sensitive techniques
- •Previous irinotecan based chemotherapy +/- bevacizumab for metastatic CCR during at least 6 weeks.
- •Irinotecan based chemotherapy does not need to be the most recent chemotherapy administrated. There are no restrictions on numbers of treatments lines before study inclusion.
- •Disease progression during irinotecan treatment or within 6 months after irinotecan treatment.
- •Karnofsky status ≥ 70% .
- •Adequate bone marrow, hepatic, renal and metabolic functions,
- •Adequate bone marrow function: neutrophils ≥ 1.5x109/ L; platelets ≥ 100x109/L; hemoglobin ≥ 9g/dL.
- •Hepatic functions as follows: total bilirubin count ≤ 1.5 x ULN; ALAT and ASAT ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastasis).
- •Renal function: creatinine clearance > 50 ml/min (according Cockcroft y Gault formulae)
- •Metabolic functions: magnesium ≥ lower limit of normal (LIN)
- •Life expectancy ≥ 3 months.
排除标准
- •Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of the skin or pre-invasive cervical cancer.
- •Unresolved toxicities from prior systemic therapy and/or radiotherapy that, in the opinion of the investigator, does not qualify the patient for inclusion.
- •Documented or suspected central nervous system metastases.
- •Any previous antitumoral treatment (chemotherapy, hormonal therapy, radiation treatment, surgery, immunotherapy, biologic therapy) ≤ 28 days before study inclusion.
- •Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia.
- •Prior anti-EGFr antibody therapy (eg, Cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, Erlotinib). Subjects who discontinue their first dose of anti-EGFR therapy (Cetuximab) because of an infusion reaction may participate in this clinical trial.
- •Paraffin-embedded tissue or unstained tumor slides from primary or metastatic tumor not available or quality ADN not available for biomarker determination by highly sensitive techniques.
- •History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis.
- •Treatment for systemic infection within 14 days before study inclusion.
- •Acute or sub-acute intestinal occlusion and /or active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day).
- •History of Gilbert's syndrome or dihydropyrimidine deficiency.
- •History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.
- •Known positive test for human immunodeficiency virus infection, hepatitis C virus, and chronic active hepatitis B infection.
- •Subject allergic to the ingredients of the study medication or to Staphylococcus protein A.
- •Any co-morbid disease that would increase risk of toxicity.
- •Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.
- •Subject who is pregnant or breast feeding.
- •Surgery (excluding diagnostic biopsy or central venous catheter placement) ≤ 28 days prior study inclusion.
- •Woman or man of childbearing potential not consenting to use adequate contraceptive precautions.
- •Subject unwilling or unable to comply with study requirements.
- •Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
研究组 & 干预措施
Experimental
Experimental
FOLFIRI + panitumumab
干预措施: panitumumab (Drug)
Experimental
Experimental
FOLFIRI + panitumumab
干预措施: FOLFIRI (Drug)
结局指标
主要结局
Objective response rate (TRO)
时间窗: 4 years
次要结局
- time to response(THR)(4 years)
- time to progression (THP)(4 years)
- duration of response (DR)(4 years)
- disease control rate (TCE)(4 years)
- time to treatment failure (THF)(4 years)
- duration of stable disease (DEE)(4 years)
- Progression free survival (SLP)(4 years)
- Overall survival (SG)(4 years)
- Adverse events(4 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical study to evaluate, in patients selected with the new technology, the efficacy and safety of the combination of Folfiri + Panitumumab in patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.EUCTR2012-001955-38-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)50
进行中（未招募）
2 期
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal CancerColorectal Cancer MetastaticNCT04169347Criterium, Inc.27
进行中（未招募）
3 期
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerColorectal CancerNCT03635021Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)419
已完成
2 期
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal CancerMetastatic Colo-rectal CancerNCT01358812Gruppo Oncologico del Nord-Ovest37
Unknown
2 期
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line TreatmentMetastatic Colorectal CancerNCT02624726Hellenic Oncology Research Group31